3435-26-5

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-6-phenylpyrimidine is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activities.
Used in Agrochemical Industry:
4-Chloro-6-phenylpyrimidine is used as a building block in the development of agrochemicals for its potential applications in crop protection and pest control.

Upstream product

• 4891-69-4 4-phenyl-6(1H)-pyrimidinone 
• 1193-21-1 4,6-dichloropyrimidine 
• 98-80-6 phenylboronic acid 
• 36822-11-4 6-phenyl-2-thiouracil 
• 497-19-8 sodium carbonate 
• 4891-69-4 4-hydroxy-6-phenylpyrimidine 

Downstream Products

• 3438-48-0 4-phenylpyrimidine 
• 4891-69-4 4-hydroxy-6-phenylpyrimidine 
• 88236-25-3 [1-(6-Phenyl-pyrimidin-4-yl)-1H-[1,2,3]triazol-4-yl]-methanol 
• 88236-31-1 [3-(6-Phenyl-pyrimidin-4-yl)-3H-[1,2,3]triazol-4-yl]-methanol 
• 88236-17-3 1-(6-Phenyl-pyrimidin-4-yl)-1H-[1,2,3]triazole-4,5-dicarboxylic acid dimethyl ester 
• 141190-58-1 4-methylthio-6-phenylpyrimidine 
• 1029718-95-3 (2S,3S)-3-amino-1-chloro-4-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-butan-2-ol 
• 1029719-33-2 (R)-5-{(S)-1-amino-2-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-ethyl}-3-[1-(3-isopropyl-phenyl)-cyclopropyl]-oxazolidin-2-one 

Relevant academic research and scientific papers

Efficient microwave-assisted synthesis of highly functionalized pyrimidine derivatives

A generally applicable one-pot procedure for the rapid, easy, and diverse asymmetric functionalization of pyrimidines was developed that requires minimum efforts for the purification of the final products. 4-Amino-6-aryl-substituted pyrimidines are prepared in good yields by combined microwave-assisted amination and Suzuki-Miyaura cross-coupling reactions. The acid-mediated amination reaction affords the products as easily separable salts in 30-40 min reaction time.

Synthesis of novel substituted pyrimidine derivatives bearing a sulfamide group and their in vitro cancer growth inhibition activity

The synthesis of two series of novel substituted pyrimidine derivatives bearing a sulfamide group have been described and their in vitro cancer growth inhibition activities have been evaluated against three human tumour cell lines (HT-29, M21, and MCF7). In general, growth inhibition activity has been enhanced by the introduction of a bulky substituent on the aromatic ring with the best compound having GI50??6?μM for all the human tumour cell lines. The MCF7 selective compounds were evaluated on four additional human invasive breast ductal carcinoma cell lines (MDA-MB-231, MDA-MB-468, SKBR3, and T47D) and were selective against T47D cell line in all cases except one, suggesting a potential antiestrogen activity.

Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead

Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma, and non-small-cell lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors, and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wild-type RET (wtRET) and its mutants (e.g., V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor, N-(2-fluoro-5-trifluoromethylphenyl)-N′-{4′-[(2′′-benzamido)pyridin-4′′-ylamino]phenyl}urea (69), endowed with a 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound. Profiling against a panel of kinases indicated 69 as a multi cKIT/wtRET/V804MRET inhibitor.

Sterically-hindered pyrimidine iridium complex phosphorescence material and preparation method thereof

The invention discloses a sterically-hindered pyrimidine iridium complex phosphorescence material and a preparation method thereof and belongs to the technical field of photoelectric phosphorescence materials. The sterically-hindered pyrimidine iridium co

Light-Emitting Element, Light-Emitting Device, Electronic Device, Lighting Device, and Heterocyclic Compound

A light-emitting element with high heat resistance and high emission efficiency is provided. A novel heterocyclic compound that can be used in such a light-emitting element is provided. One embodiment of the present invention is a light-emitting element w

ORGANOMETALLIC IRIDIUM COMPLEX, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE

An organometallic iridium complex has high emission efficiency and a long lifetime. The iridium complex includes the structure represented by Formula (G1). In the formula, Ar represents a substituted or unsubstituted arylene group having 6 to 13 carbon at

COMPOUND, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE, AND LIGHTITNG DEVICE

Provided is an organometallic iridium complex, as a novel material, which has favorable light emission efficiency and a long lifetime, and emits yellow light. The organometallic iridium complex is represented by general formula (G1), and has a structure i

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntingtons disease

We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against other kynurenine pathway enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.

Organic Light-Emitting Element, Organometallic Complex, Light-Emitting Device, Electronic Appliance, and Lighting Device

Disclosed is a phosphorescent organometallic complex having: a 6-membered aromatic heterocycle having a nitrogen atom; iridium or platinum to which the nitrogen atom coordinates; and an aryl group which is bonded to an α-carbon of the nitrogen atom and is ortho-metalated with the iridium or platinum, where at least one of the aromatic heterocycle and the aryl group has an alicyclic hydrocarbon having an intramolecular carbon-carbon bridged bond as a substituent. The ability of the bulky structure of the alicyclic hydrocarbon to inhibit aggregation of the organometallic complex, concerted with the strong electron-donating property of the alicyclic hydrocarbon to the aromatic heterocycle or the aryl group, contributes to the increase in absorption coefficient and phosphorescent efficiency of the organometallic complex. The improved absorption coefficient and the phosphorescent efficiency allow the formation of a light-emitting element with excellent external quantum efficiency over 25%.

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.